Use of HMG-CoA Reductase Inhibitors in the HIV Population: Implications for Individualized Treatment Selection

Advani, Ashish; Patel, Manish I.; Pichardo, Roberto V.; Whitty, Yolanda; Advani, Shreena

doi:10.18553/jmcp.2014.20.3.262

Cited by 2 publications

(1 citation statement)

References 44 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This inhibition leads to adipocyte cell death and reduction in the adipocyte regeneration rate. These phenotypic changes lead to increases in circulating triglycerides and lipid derangements, including increased total cholesterol, low‐density lipoprotein (LDL) cholesterol and triglyceride levels alongside decreased high‐density lipoprotein (HDL) cholesterol levels .…”

Section: Vascular Manifestations Of Hiv Infectionmentioning

confidence: 99%

HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review

Lambert

Sandesara

Hirsh³

et al. 2015

HIV Medicine

View full text Add to dashboard Cite

The advent of potent highly active antiretroviral therapy (HAART) for persons infected with HIV-1 has led to a "new" chronic disease with complications including cardiovascular disease (CVD). CVD is a significant cause of morbidity and mortality in persons with HIV infection. In addition to traditional risk factors such as smoking, hypertension, insulin resistance and dyslipidaemia, infection with HIV is an independent risk factor for CVD. This review summarizes: (1) the vascular and nonvascular cardiac manifestations of HIV infection; (2) cardiometabolic effects of HAART; (3) atherosclerotic cardiovascular disease (ASCVD) risk assessment, prevention and treatment in persons with HIV-1 infection.

show abstract

Section: Vascular Manifestations Of Hiv Infectionmentioning

confidence: 99%

HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review

Lambert

Sandesara

Hirsh³

et al. 2015

HIV Medicine

View full text Add to dashboard Cite

show abstract

Recommendations for Managing Drug–Drug Interactions with Statins and HIV Medications

Lamprecht

Page

Saseen

2017

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

The discovery of antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) has enabled individuals to live longer. As a result, HIV is now often considered a chronic condition. However, as a result of the increase in longevity or the HIV treatment modalities themselves, individuals with HIV are at high risk for the development of atherosclerotic cardiovascular disease. Therefore, these patients should be optimized with pharmacologic therapy to lower their cardiovascular risk through the addition of statin therapy to their regimen. Unfortunately, many medications utilized to treat HIV interact with this class of agents, making prescribing of statin therapy in these patients challenging. While several classes of ARTs do not pose an increased risk of drug-drug interactions with statins, HIV treatment often requires several combinations of medications, enhancing the complexity and drug-drug interaction risk. Clinicians should be aware of interactions with statins and ART and carefully review the degree and clinical significance of each particular medication. With this understanding, the appropriate statin as well as statin dose can be selected in order to optimize the treatment of this patient population, while minimizing the potential risk of adverse effects.

show abstract

Use of HMG-CoA Reductase Inhibitors in the HIV Population: Implications for Individualized Treatment Selection

Cited by 2 publications

References 44 publications

HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review

HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review

Recommendations for Managing Drug–Drug Interactions with Statins and HIV Medications

Contact Info

Product

Resources

About